ANRO | Alto NeuroscienceNYSEHealthcareCommon stock golden cross and death cross projections, cross tests and history

$22.70
+$0.51 (+2.30%)

Alto Neuroscience (ANRO) is a NYSE-listed common stock that Cruxta has tracked for 50/200 crosses since 2025.

Right now the daily is the chart to watch. The 50 SMA has sat above the 200 since Sep 2025, but the two have been closing on each other and a death cross is projected within 20 bars. Price sits below the 50 and the 200 on the daily and the 4-hour.

Timeframe summary

Daily as of 3 Nov 16:00 ET

Price
below both $22.70 vs 50 $27.76 / 200 $24.31
Projection
Death cross projected in 13 bars
Test
No active test
Last cross
Golden cross 11 Sep 2025 ยท projected 22 bars out

Weekly

No weekly data

4-hour as of 3 Nov 13:30 ET

Price
below both $22.90 vs 50 $23.44 / 200 $27.64
Projection
No cross projected
Test
No active test
Last cross
Death cross 14 Oct 2026 ยท projected 30 bars out

Cross history

2
crosses on record since 2025
1 golden1 death
Full cross history โ†’
CrossedDirectionTimeframeProjectedCross test
14 Oct 2026Death4-hour30 bars outNot tested
11 Sep 2025Golden steepdaily22 bars outNot tested

About ANRO

ExchangeNYSE
InstrumentCommon stock
Median $ volume, 60 d$13.3M
4-hour coverageYes, since Oct 2025
History on recordSince 2025
SectorHealthcare
Cap bandsmall

Cruxta · 50/200 moving-average crosses on US equities. Recorded crosses are observations. Projected crosses are projections, not advice.